Schrödinger, Inc.

Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications globally. The company operates in two segments: Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, both internally and through collaborations. For example, Schrödinger has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Founded in 1990 and headquartered in New York, New York, the company leverages its technology to accelerate the design of new therapeutics and materials.

Schrödinger, Inc. is listed on the NasdaqGS exchange under the ticker symbol SDGR. Its shares are traded in US Dollars (USD). The company is headquartered in New York, New York, United States, and operates primarily in the US market, though its computational platform serves clients globally in the life sciences and materials science industries.

Schrödinger, Inc. operates in the Healthcare sector, specifically within the Health Information Services industry. The company's computational platform and software are used primarily for drug discovery and materials science, which falls under the broader healthcare and life sciences umbrella. Its Drug Discovery segment further emphasizes its role in developing novel therapeutics, while the Software segment serves both life sciences and materials science industries.

Schrödinger, Inc. is headquartered in New York, New York, United States. The company was incorporated in 1990 and has a global reach, serving customers in the life sciences and materials science industries worldwide. Its physics-based computational platform is used by researchers and companies internationally to discover novel molecules for drug development and materials applications. The company's Drug Discovery segment also engages in collaborations, such as with Novartis Pharma AG, to advance preclinical and clinical programs.

Schrödinger generates revenue through two main segments: Software and Drug Discovery. The Software segment sells its physics-based computational platform to customers in the life sciences and materials science industries, enabling them to transform molecular discovery. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, both internally and through collaborations. For instance, Schrödinger has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. This segment may generate revenue through milestones, royalties, or licensing fees from partnered programs.